Tianyue Zhou
Chilly, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease.
Journal: Journal of neuromuscular diseases
Published: May 21, 2025
Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial.
Journal: Journal of neurology
Published: February 05, 2025
Corrigendum to "Home infusion experience in patients with Pompe disease receiving avalglucosidase alfa during three clinical trials" [Molecular Genetics and Metabolism, 143 (2024) 108608].
Journal: Molecular genetics and metabolism
Published: January 09, 2025
The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa.
Journal: The Journal of pediatrics
Published: July 05, 2024
Home infusion experience in patients with Pompe disease receiving avalglucosidase alfa during three clinical trials.
Journal: Molecular genetics and metabolism
Published: June 13, 2024
Post-hoc Nonparametric Analysis of Forced Vital Capacity in the COMET Trial Demonstrates Superiority of Avalglucosidase Alfa vs Alglucosidase Alfa.
Journal: Journal of neuromuscular diseases
Published: December 31, 2023
Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: A pooled analysis of clinical trials.
Journal: Molecular genetics and metabolism reports
Published: December 06, 2023
Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial.
Journal: Molecular genetics and metabolism
Published: July 03, 2023
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Journal: JAMA neurology
Published: April 10, 2023
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease.
Journal: Neurology
Published: August 23, 2021
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Journal: The Lancet. Neurology
Published: February 24, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026